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Abstract
Objective: To assess whether VEGF-C expression can predict the re-
sponse to neoadjuvant chemotherapy and pelvic lymphnode metas-
tases in bulky cevical cancer.
Methods: Seventeen cervical cancer stage IB2 and IIA2 cases during
the period of July 2009 until June 2010 were collected consecutively and
given neoadjuvant chemotherapy (NAC) PVB prior radical surgery. Re-
sponse to treatment was evaluated based on the change of tumour size.
VEGF-C expression was examined immunohistochemically at tumour bi-
opsy before chemotherapy. The presence of lymphnode metastases his-
topathologically were obtained from pelvic lymphnode dissection. The
difference and correlation of response and metastases on VEGF-C ex-
pression were analized statistically. The validity of the cut off percentage
of immunopositive cells to VEGF-C to identify non responding and me-
tastatic cases was calculated with the ROC. Multivariate analysis were
done to determine the predictor of no response to chemotherapy.
Results: Clinical response, using the RECIST version 1.1 criteria, was
found in 41.18% cases and lymphnode metastases were found in
27.27% cases. VEGF-C was expressed in all cases. Statistically, there
were no significant differences and correlation in response to treat-
ment and pelvic lymphnode metastases on VEGF-C expression. At
the cut off ≥ 76% immunopositivity to VEGF-C, the sensitivity to
identify no response and the specificity to identify response to NAC
are 70.00% and 71.43% respectively (LR+ 2.45 and LR- 0.42);
whereas at the cut off ≥ 75% immunopositivity to VEGF-C, the sen-
sitivity to identify lymphnode metastases and the specificity to iden-
tify no lymphnode metastases are 100.00% and 75.00% (LR+ 4.0
dan LR- 0). With multivariate analysis using logistic regression, the
cut off ≥ 76% immunopositive cells to VEGF-C were found to have
positive coefficient, largest OR and statistic score, 1.93, 6.88 (96% CI
OR 0.45; 104.34) and 41 respectively, to predict non responders in
a prediction score model.
Conclusion: VEGF-C expression on biopsy specimen bulky cervical
cancers can not differentiate cases that respond to NAC and metas-
tases to the pelvic lymphnode from that do not. The cut off ≥ 76%
immunopositive cells to VEGF-C in a prediction model can be used
as an alternative predictor to identify non responders.
[Indones J Obstet Gynecol 2012; 36-3: 144-9]
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Abstrak
Tujuan: Untuk menilai apakah ekspresi VEGF-C dapat memprediksi
respons terhadap kemoterapi neoajuvan dan metastasis ke kelenjar
getah bening pelvis pada kanker leher rahim lesi besar.
Metode: Sebanyak 17 kasus kanker leher rahim stadium IB2 dan IIA2
dikumpulkan secara konsekutif selama periode Juli 2009-Juni 2010
dan diberi kemoterapi neoajuvan PVB sebelum bedah radikal.
Penilaian respons terhadap kemoterapi didasarkan pada perubahan
ukuran tumor. Ekspresi VEGF-C diperiksa secara imunohistokimia
dari biopsi tumor sebelum pemberian kemoterapi. Adanya metastasis
ke kelenjar getah bening pelvis diperoleh dari diseksi kelenjar getah
bening pelvis. Uji beda dan korelasi respons terapi dan metastasis tu-
mor pada ekspresi VEGF-C dianalisis secara statistik. Reliabilitas cut
off persentase imunopositif VEGF-C untuk mengidentifikasi kasus tidak
respons dan bermetastasis ditentukan dengan ROC. Analisis multi-
variat dilakukan untuk menentukan prediktor tidak adanya respons
terhadap kemoterapi.
Hasil: Respon klinis, menggunakan kriteria RECIST 1.1, dijumpai pada
41,18% kasus dan metastasis kelenjar dijumpai pada 27,27% kasus.
VEGF-C diekspresikan pada seluruh kasus. Secara statistik tidak di-
jumpai perbedaan dan korelasi respons terapi dan metastasis kelenjar
yang bermakna pada ekspresi VEGF-C. Pada cut off ≥ 76% imunopo-
sitif terhadap VEGF-C, sensitivitas untuk mengidentifikasi kasus tidak
respons dan spesifisitas untuk mengidentifikasi kasus respons ter-
hadap kemoterapi neoajuvan masing-masing adalah 70,00% dan
71,43% (LR+ 2.45 dan LR- 0.42); sementara pada cut off ≥ 75% imu-
nopositif terhadap VEGF-C, sensitivitas untuk mengidentifikasi metas-
tasis kelenjar dan spesifisitas untuk mengidentifikasi tidak ada metas-
tasis kelenjar adalah 100,00% dan 75,00% (LR+ 4,0 dan LR- 0). De-
ngan analisis multivariat menggunakan regressi logistik, cut off ≥ 76%
imunopositif terhadap VEGF-C dijumpai mempunyai koefisien positif,
OR dan skor statistik terbesar, masing-masing 1,928 dan 6,88 (96% CI
OR 0,45; 104,34) dan 41, untuk memprediksi kasus tidak respons di
dalam suatu model skor prediksi.
Kesimpulan: Ekspresi VEGF-C pada spesimen biopsi kanker leher
rahim stadium IB2 dan IIA2 tidak dapat membedakan kasus yang
berespons terhadap kemoterapi neoajuvan maupun yang bermetasta-
sis dari yang tidak. Cut off ≥ 76% imunopositif terhadap VEGF-C di
dalam suatu model skor prediksi dapat digunakan sebagai alat
prediktor alternatif untuk menemukan kasus tidak respons.
[Maj Obstet Ginekol Indones 2012; 36-3:144-9]
Kata kunci: ekspresi VEGF-C secara imunohistokimia, kanker leher ra-
him lesi besar, kemoterapi neoajuvan, prediksi respons dan metastasis
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INTRODUCTION
Cervical cancer is the 3rd most common cancer in
women, and the seventh overall, with an estimated
530,000 new cases in 2008.1 In Indonesia, based
on the National Cancer Registry on 2010, the inci-
dence rate of cervical cancer accounts for 27.89%
of cancer in women and from 509 clinical staging
done on 2009, there were 18 and 36 cases with
stage IB2 and IIA disease.2
Caused by the high incidence of pelvic lymph-
nodes metastases and disease recurrence in bulky
tumour, FIGO (Federation of International Gyne-
cologists and Obstetricians) on 1995 divided cervi-
cal cancer stage IB into 2 sub-stages, and also stage
IIA on 2008 (Revised FIGO staging for cervical can-
cer). The sub-stages represents lesion size ≤ 4 cm
and > 4 cm (bulky tumour).3-4
Although chemoradiation has already been ac-
cepted as standard therapy for cervical cancer pa-
tients with bulky tumour size, the role of neoadju-
vant chemotherapy (NAC) before radical surgery
need to be explored further because it can reduce
tumour size and improve overall survival.5-6 On the
other hand, delay of definitive therapy, acceleration
of tumour growth, and even metastases can be ex-
pected in patients who do not shows any response
to this approach. A convenient predictor that can
predict response to neoadjuvant chemotherapy
and metastases to the pelvic lymphnodes before
choosing an available therapy modality, has be-
come an important issue.7
A biomarker is still controversial as a predictor
of response to chemotherapy and in testing metas-
tases.8-9 But for Indonesia, where sophisticated
imaging techniques are not always available and
considered expensive, Vascular Endothelial Growth
Factor-C (VEGF-C) that has been shown to have a
role in the development and progression of cancer
could be a valuable alternative predictor.10
In cervical cancer, including bulky lesion, VEGF-
A on previous studies has been shown to have a
role in prediction of response to neoadjuvant che-
motherapy11-13 and also VEGF-C serum level in
prediction of metastases.14 In this study we want
to know whether VEGF-C expression can predict
response and metastases to pelvic lymphnodes be-
fore neoadjuvant chemotherapy in order to im-
prove patient management.
METHODS
From 17 cervical cancer patients stage IB2 and IIA2,
studied in Dr. Cipto Mangunkusumo Jakarta and
Dr. Hasan Sadikin Bandung referral hospital (Indo-
nesia) from July 2009 until June 2010 and ap-
proved by the tumour board to give neoadjuvant
chemotherapy, were collected data about tumour
size, histopathology, tumour VEGF-C expression
and pelvic lymphnode status. All subjects, that had
no history of therapy and been diagnosed his-
topathologically, had given written informed con-
sent.
Chemotherapy in this study consists of cisplatin
50 mg/m2, vincristine 2 mg/m2 and bleomycin 15
mg at 7 days intervals for 3 cycles. After receiving
complete chemotherapy, patients considered suit-
able for surgery, had been performed radical hys-
terectomy and pelvic ≤ lymphnode dissection in 6
weeks. Metastases to the lymphnodes and other
high risk factors were evaluated histopathologi-
cally. Patients who did not respond or not suitable
for surgery received radiation.
Response criteria to therapy was based on re-
vised RECIST (Response Evaluation Criteria in
Solid Tumours) (1.1). Measurement of the tumour
diameter, was done in 4 weeks before and in 3
weeks after chemotherapy, through pelvic exami-
nation using a tampon forcep measured with a
ruler (cm) in 3 dimensions. If the stage of the dis-
ease clinically progressed the response was consid-
ered progressive. If the response was clinically
complete, with no evidence of primary tumour, pel-
vic lymphnode and parametrial involvement his-
topathologically, the response was considered as
complete pathologic response.15-16
Cervical biopsy specimen, preserved with 10%
formalin and embedded in paraffin to build tissue
blocks, were processed for histologic examination
with hematoxylin and eosin (H&E) staining and im-
munohistochemistry analysis using avidin-biotin-
peroxidase method. VEGF-C protein expression
was detected with mouse anti-human monoclonal
VEGF (C-1) antibody using Star Trek Universal HRP
Detection System (Biocare Medical, LLC, Concord
CA, USA) as a detector. Paraffin blocks were sec-
tioned 4μm thick, developed in waterbath, adhered
to object glasses and incubated at 60°C for 30 mi-
nutes. The slides were deparaffinized in xylene, de-
hydrated through graded alcohol concentrations,
incubated at 94°C with 0.5% methanol-H2O2 for 30
minutes, and finally soaked in Tris EDTA (TE) so-
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lution as pretreatment for antigen retrieval. The
slides were then incubated using microwave at 90-
100°C followed at 50-60°C for 5 minutes respec-
tively. After cooling at room temperature and
washed with Phosphate-Buffer Saline (PBS) at pH
7.4, to the slides were added a protein blocking
agent to block background sniper. The primary an-
tibody was then added and incubated for 30-45
minutes at room temperature and washed with
PBS. After adding the secondary antibody, biotiny-
lated secondary antibody (Trekkie Universal Link),
and bound with Horseradish peroxidase (HRP) la-
beled with septravidine, the antigen antibodi com-
plex was visualized with diaminobenzidine that is
brown stained. Positive controls originates from
colon tissue that express VEGF-C and negative con-
trols originates from the study cervical cancer tis-
sue without giving primary antibody.
VEGF immunoreactivity was scored based on
brown staining of cytoplasm of tumour cells at im-
munohistochemistry slides semiquantitatively us-
ing the IRS (Immunoreactive Scoring System).17
(Figure 1).
 Assesments were done independently by two
investigators, who were not aware of the clinical
outcome, and then evaluated together until a con-
sensus reached.
Statistical analysis were done using SPSS 15. Bi-
variate analysis were calculated using Fisher exact,
Pearson chi square and Wilcoxon signed-rank tests.
Probability was considered significant if p value
<0.05 with confidence interval 95%. Correlation
beween variables were evaluated with Spearman
test. A ROC (Receiver Operating Characteristic)
analysis and a multivariate analysis using logistic
regression, were done to determine a reliable cut
off point of the percentage immunopositive cells to
VEGF-C and a predictive score.
RESULTS
Thirty cases were collected consecutively. As many
as 13 cases (43%) had to excluded, primarily
caused by delay in chemotherapy schedule.
The average age of the cases is 45.20 years and
cummulatively were more at the age <50 years.
Other clinicopathologic characteristics are as listed
in Table 1.
Table 1. Clinicopathologic characteristics
Variables n % Avg SD 95% CI p
Age (year)
< 50
≥ 50
17
13
56.7
43.3
45.2 9.26
BMI
18.5-24.99
≥ 25
23
 7
76.7
23.3
23.1 3.16
T shape
Exophytic
Endophyt.
26
 4
86.7
13.3
Stage disease
IB2
IIA2
20
10
66.7
33.3
Tumour size
Before NAC
After NAC
17
11
100
64.7
4.76
2.9 
0.41
1.69
4.50-5.05
1.76-4.04
0.008*
Histologic type
Squamous
Adenoca
Adenosq
Others
12
 3
 1
 1
70.6
17.6
 5.9
 5.9
Cell diff
G1-G2
G3
11
 6
64.7
35.3
LVSI
Negative
Positive
16
 1
94.1
 5.9
* Wilcoxon signed-rank test
Avg=average
All cases expressed VEGF-C. After neoadjuvant
chemotherapy there was a significant decrease in
tumour size (p = 0.0087). From 7 responding cases
(41.18%), 2 (11.76%) showed clinical (CR) and
pathological complete response (CPR). To all cases
that were considered respectable were performed
radical hysterectomy and pelvic lymphnode dissec-
 
Figure 1. VEGF-C expression (magnified 400x) at IHC slides.
A. Negative expression; B. Weak expression;
C. Moderate expression; D. Strong expression.
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tion (10 cases, 58.82%), while cases that were con-
sidered too large or disease progressed were irra-
diated (7 cases, 41.18%). To one irradiated case,
was performed also lymphnode dissection. Tu-
mour cells at surgical margins after radical surgery
were found only in 1 of 10 cases (10%).
The p values of response to NAC at clinico-
pathologic characteristics were not significantly
different. Also at VEGF-C expression, respectively
at every grade, there were no statistical differences
(p = 0.65, 0.69 dan 0.67) (Table 2).
Table 2. Differences in response to NAC at VEGF-C
expression
VEGF-C
expression Response
No
Response Total p
Weak 4 (23.53%)  6 (35.29%) 10 (58.82%) 0.65*
Moderate 2 (11.76%)  3 (17.65%)  5 (29.41%) 0.69*
Strong 1 ( 5.88%)  1 ( 5.88%)  2 (11.76%) 0.67*
Total 7 (41.18%) 10 (58.82%) 17 (100.0%)
* Fisher exact test
Metastases to the pelvic lymphnodes were found
in 3 cases (27.27%). Metastatic tumour cells, re-
spectively were found at 1 of 3 pelvic lymphnodes
with infiltration to the right parametrium, at 1 of
5 obturator lymphnodes, and at 3 pelvic lymph-
nodes each side of 19 lymphnodes dissected. There
were no statistically significant differences in
metastases to the pelvic lymphnodes at VEGF-C
expression (p=0.44). (Table 3)
Table 3. Differences in lymphnode metastases at VEGF-C
expression
VEGF-C
expression Positive Negative Total p
Weak 1 ( 9.09%) 6 (54.55%)  7 (63.64%) 0.44*
Moderate 1 ( 9.09%) 1 ( 9.09%)  2 (18.18%)
Strong 1 ( 9.09%) 1 ( 9.09%)  2 (18.18%)
Total 3 (27.27%) 8 (72.73%) 11 (100.0%)
* Pearson chi square
With Spearman test, a correlation could not be
demonstrated between VEGF-C expression and re-
sponse; neither also between VEGF-C expression
and metastases (Spearman’s rho = -0.0286, 0.3858
and p = 0.9133, 0.2413 respectively).
Because bivariate analysis and Spearman test
could not answer the hypothesis of this study, we
decide to determine a reliable cut off point at the
percentage of immunopositive cells to VEGF-C to
identify non responding and metastatic cases with
the ROC analysis. The rationality to use the per-
centage of immunopositive cells to VEGF-C, be-
cause this continuous numeric data were not cate-
gorized like the IRS that could hide the differences.
On each percentage, we tested the sensitivity and
specificity, positive likelyhood ratio (LR+) and
negative likelyhood ratio (LR-).
The reliable cut off point to identify non re-
sponder was at ≥ 76% immunopositive cells (sen-
sitivity 70% and specificity 71.43%, correctly clas-
sified 70.59%, with LR+ 2.45 and LR- 0.42), al-
though not statistically different (p=0.09). The area
under the curve (AUC) at the ROC analysis was
0.61 with SE 0.17 (95% CI 0.27 - 0.95). (Figure 2)
Whereas the reliable cut off point to identify me-
tastatic cases, was at ≥ 75% immunopositive cells
(sensitivity 100% and specificity 75.00%, correctly
classified 81.82%, with LR+ 4.0 and LR- 0). The
AUC at the ROC analysis was 0.75 with SE 0.16
(95% CI 0.43-1.00). (Figure 3)
Area under ROC curve = 0.7500
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Figure 3. ROC analysis curve of metastases at VEGF-C
 immunopositivity
Area under ROC curve = 0.6071
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Figure 2.  ROC analysis curve of response at VEGF-C
 immunopositivity
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At the multivariate analysis with logistic regres-
sion, the variables that included in the prediction
model of no response are as listed in Table 4. A
positive coefficient, highest OR (Odds ratio) and
statistical score were found at the variable ≥ 76
percentage immunopositivity to VEGF-C to predict
no response, respectively 1.93, 6.88 (96% CI OR
0.45; 104.34) and 41.
If we compared the AUC from the mathematical
model with the AUC from the model that has been
transformed into statistical score, there were no
statistical differences (p=0.3068). The statistical
score with cut off ≥ 52 can be used as a predictor
of no response (sensitivity 60%, specificity 85.71%
and accuracy 70.59%).
DISCUSSION
The number of complete clinical response in this
study are smaller compared with the results in Mo-
darress et al and Benedetti-Panici P et al studies
(respectively 16.7% and 78%); either is complete
pathologic response compared with the studies of
Choi CH et al (27.6%), but similar with the studies
of Modarress et al and Benedetti-Panici P et al (re-
spectively 10 and 13%).
In this study, despite VEGF-C was expressed in
all cases, it could not differentiate responder from
non-responder neither also metastatic from non-
metastatic cases. These observations are different
with that reported by Choi CH et al and Cheng WF
et al at VEGF expression,11-13 and Andrijono dan
Priyanto H at VEGF-C serum level in their studies.14
The differences of the results reported in the
studies mentioned above at response and metasta-
ses, is probably caused by the sample size needed
to see differences in a relatif homogen percentage
of responder and non responder population (41.18%
vs 58.82%) is larger, although the minimum sam-
ple size to see differences in response and metas-
tases at VEGF-C expression has been reached. This
difference can be referred as a statistical bias by
chance.
At the ROC analysis, the percentage =76 and =75
immunopositive cells to VEGF-C, respectively for
no response and metastases, are reliable and the
AUC of both ROC curves in this analysis (0.61 and
0.75 respectively) were considered to have fairly
and good reliability. With multivariate analysis, al-
though statistically not significant (p = 0.17), the
variable percentage ≥ 76 immunopositive cells to
VEGF-C can be demonstrated as the strongest pre-
dictor of no response (Table 4).
The variables included in the prediction mo-
del, with cut off ≥ 52 prediction score, can fur-
ther be used as a tool to predict non responding
cases; although this conclusion should be further
studied with more samples. If the prediction score
found for a certain cervical cancer with bulky le-
sion is ≥ 52, chemoradiaton would be more reason-
able than neoadjuvant chemotherapy followed
with radical surgery as the definite therapy. Alter-
natively, if the choice is radical surgery anti VEGF
should be added, although this approach in cervical
cancer need to be explored.
CONCLUSION
VEGF-C expression in this study can not differenti-
ate non responding from responding and metas-
tatic from non-metastatic cases in stage IB2 and
IIA2 cervical cancer given neoadjuvant chemother-
apy. The prediction score, using ≥ 76 percentage
immunopositive cells, with cut off ≥ 52 could be a
valuable alternative tool in this approach.
Table 4. Prediction model of no response to NAC with statistical score
Variable Coefficient SEcoefficient z OR
95%
CI OR p Score
% immunopositive (≥ 76) 1.93 1.39 1.39 6.88  0.45; 104.34 0.17 41
Hard lymphocyte reaction 0.59 1.73 0.34 1.81 0.06; 53.83 0.73 10
Moderate diff. 1.57 1.98 0.79 4.79  0.10; 233.61 0.43 23
Poor diff. –.005 1.77 –.003 1.00 0.03; 32.00 0.10  0
BMI < 23.1 0.55 1.45 .378 1.73 0.10; 29.66 0.70 11
Constanta –2.28 2.16 –1.06
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In the immunohistochemistry report of VEGF-C
expression, the percentage of immunopositive cells
to VEGF-C need to be included in order to have a
more clearer impression of the immunopathology
of the disease.
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